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OBJECTIVES: To estimate the budget impact of adding omalizumab to standard 
therapy (ST) in patients with uncontrolled severe allergic asthma, from the 
perspective of the Brazilian private health care system, over a 5-year time 
horizon. METHODS: A budget impact model was developed to calculate the 
budget impact for Brazil, based on local epidemiological and drug cost data. The 
eligible population was based on the following inputs: 2013 population estimate 
(age ≥6 years): 183 million; prevalence of asthma: 10%; proportion of patients 
diagnosed and receiving treatment: 6.5%; percentage with allergic asthma: 69%; 
percentage with immunoglobulin E (IgE) ≥30 IU/mL: 78.7%; percentage with 
uncontrolled, severe disease: 2.4%; proportion of population using the private 
health care system and medications: 25.1%. For the following years, an annual 
population growth rate of 1.17% was assumed. Average doses, resource 
utilization per exacerbation and proportion of patients who respond to 
omalizumab were obtained from the INNOVATE trial. Direct costs, including 
omalizumab purchase and the costs of health care consumption related to 
exacerbations and routine visits. These costs were calculated from the 
perspective of the private health care payer. Omalizumab uptake was assumed 
to be 17%, 35%, 55%, 75% and 95% of eligible population for years 1 to 5, 
respectively. RESULTS: The number of patients eligible for add-on omalizumab 
therapy that met the eligibility criteria was estimated to be around 3,887 in the 
first year. The annual budget impact of omalizumab was approximately BRL25 
million, BRL50 million, BRL77 million, BRL104 million and BRL131 million for 
years 1 to 5, respectively (BRL1=USD0.492). CONCLUSIONS: The budget impact 
for the private health care system in Brazil of adding omalizumab to ST was 
approximately BRL131 million at the end of year-5. Considering that the total 
population using the private health care system in Brazil is around 45.4 million, 
this represents a relatively small impact on the payer’s budget, of BRL2.90 per 
beneficiary.  
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OBJECTIVES: The prevalence of COPD in Brazil is estimated in 15,8% and it is the 
fourth cause of hospitalization a in the Brazilian public health system (SUS) in 
the last 10 years. Until recently only the short-action and long-action β2-agonists 
were distributed to COPD patients by SUS. The aim of this study was to 
determine the expected consequences on the cost and effectiveness and the 
budgetary impact of the recent introduction in SUS of budesonide and 
beclomethasone for the treatment of COPD patients. METHODS: Systematic 
review of the literature and development of a decision analytic model to 
demonstrate the immediate response to treatment with inhaled steroids and 
project the results in terms of effectiveness and cost based on current knowledge 
of the natural history of the disease. The analysis was performed for a 
hypothetical cohort of adults with forty or more years with COPD GOLD stage II, 
III or IV. The primary perspective of the study was SUS. Data sources were the 
medical literature, official published prices of SUS for medicines and DATASUS 
(SUS database). RESULTS: Corroborating the results of other systematic reviews 
we also did not detect differences in efficacy and safety between budesonide and 
beclomethasone therefore we performed a cost-minimization analysis. Both 
steroids reduced the exacerbation rate in about 40%. The annual costs of the 
treatment with budesonide and beclomethasone were 714,29 and 786,77, 
respectively. The parameter that led to greater variation in the model was the 
cost of hospitalizations with ICU stays. The projected budget impact for 
introduction of inhaled corticoids (50%/50%) for COPD treatment in 2013 is about 
R$345 million reais. CONCLUSIONS: There are no differences in efficacy and 
safety between the studied inhaled steroids. To achieve about 40% reduction in 
the exacerbation rate the budget impact for SUS in 2013 would be of 
approximately R$345 million reais.  
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OBJECTIVES: To evaluate the clinical and economic burden of chronic 
obstructive pulmonary disease (COPD) in the U.S. veteran population. METHODS: 
Patients diagnosed with COPD (International Classification of Disease 9thRevision 
Clinical Modification [ICD-9-CM] diagnosis codes 490.xx, 491.xx, 492.xx, 494.xx, 
495.xx, 496.xx) were included in this retrospective study (October 1, 2005 - May 
31, 2012) conducted using the Veterans Health Administration (VHA) Medical 
SAS Datasets. Health care resource utilization and costs were assessed for the 
12-month follow-up period. Patients' clinical and discharge statuses were 
examined for the 12-month baseline period. Means and standard deviations 
were provided for continuous variables. Numbers and percentage were provided 
for categorical variables. All descriptive statistical analyses were performed 
using SAS v9.3 software. RESULTS: Among all study patients diagnosed with 
COPD (772,898), major comorbidities during the baseline period included 
hypertension (27.9%), depressive disorder (6.72%), chronic ischemic heart disease 
(5.18%) and shortness of breath (4.73%). The most common medications 
prescribed within 60 days of disease identification were simvastatin (27.45%), 
lisinopril (20.63%), omeprazole (19.47%) and aspirin (12.19%). In the 12-month 
follow-up period, 49.61% of patients were prescribed short-acting b-agonists 
(SABAs) while only 60 patients were prescribed long-acting b-agonists (LABAs). 
Outpatient visits (99.75%) occurred more frequently than inpatient visits 
(22.28%). Inpatient ($8,420), outpatient ($8,584) and pharmacy costs ($1,746) 
combined for a total expenditure of $18,750. CONCLUSIONS: Patients were 
prescribed simvastatin, lisinopril and omeprazole more often within 3 months 
after disease identification than other medications. Within 1-year post-
diagnosis, SABAs were prescribed more often than LABAs as a treatment for 
COPD.  
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OBJECTIVES: Health care cost data for pulmonary arterial hypertension (PAH) are 
scarce, especially for important morbidity events like hospitalizations, owing to 
the absence of a unique ICD-9-CM code. This study assessed inpatient costs and 
length of stay (LOS) among US patients with PAH. METHODS: A retrospective 
analysis was performed using data (January 2007–December 2011) from adult 
enrollees with Commercial or Medicare Advantage with prescription drug 
coverage from a large health plan. PAH patients were identified based on both ≥1 
medical claim with an ICD-9-CM code for primary pulmonary hypertension (PH) 
(416.0) or other chronic pulmonary heart disease (416.8), and ≥1 pharmacy claim 
for a medication indicated for PAH or frequently used in PAH. Patients had to 
have ≥365 days of enrollment prior to index date (study inclusion) and 180 days 
during follow-up. Discharge diagnoses being unavailable, the principal diagnosis 
for each hospitalization was defined as the most frequent primary diagnosis on 
that hospitalization's facility claims. Total hospitalization costs (inflated to 2011 
USD using the CPI-U) and LOS, stratified by payer (excluding dual eligibility) and 
principal diagnosis, were analyzed with descriptive statistics. RESULTS: The 4009 
PAH patients (52% female, mean±SD age 60±14 years) incurred 5582 
hospitalizations. Hospitalization cost was $34,123±107,005 (mean±SD), and was 
nearly 3 times higher for hospitalizations with Commercial ($46,118±135,137, 
n=3322) than Medicare Advantage coverage ($16,319±30,046, n=2244). Average 
cost was higher for hospitalizations with a principal diagnosis of PH (416.0 or 
418.6) than other principal diagnoses ($49,722±181,878, n=878 vs $31,211± 85,821, 
n=4704). Average LOS was 11.7±20.8 days, and was longer for hospitalizations 
with Medicare than Commercial coverage (12.8±21.2 vs 10.9±20.4 days), and for 
hospitalizations with PH as principal diagnosis compared with other principal 
diagnoses (15.0±30.5 vs 11.1±18.3 days). CONCLUSIONS: Long durations and high 
incurred costs for PH-related hospitalizations reveal the severe morbidity, health 
care, and patient burden of PAH.  
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OBJECTIVES: Severe, poorly-controlled asthma affects a minority of asthma 
patients but accounts for a disproportionately large amount of asthma-related 
medical expenditures. Based on 2007 NIH (NHLBI EPR-3) guidelines, oral 
corticosteroids (OCS) are recommended therapy for step 6 management of severe 
persistent asthma. We sought to better understand asthma-related health care 
utilization in patients who require frequent OCS. METHODS: We examined 
Thomson Reuters MarketScan claims data (2006-2010) to identify patients aged 
≥12 years, continuously enrolled for ≥24 months, with OCS-dependent asthma, 
defined as ≥3 30-day OCS fills over a 12-month period and a primary asthma 
diagnosis (ICD-9 493) within 12 months of the first OCS fill. Excluded were 
patients with COPD including emphysema, cystic fibrosis, acute respiratory 
failure, and 29 other conditions that may require frequent OCS. Asthma-related 
health care utilization was examined during the 12-month period following 
patients’ first OCS fill. RESULTS: Among the 10,319 patients meeting study 
criteria, 6,941 (67.3%) were female; the mean (SD) age at first OCS fill was 57.9 
(15.9). The most common comorbid diagnoses were allergic rhinitis (n=1,507; 
14.6%), chronic sinusitis (n=1,236; 12.0%), pneumonia (n=1,066; 10.4%), and 
gastroesophageal reflux disease (n=1,036; 10.0%). During 12-month follow-up, 
patients received a mean (SD) of 6.2 (3.6) OCS fills. OCS was used in conjunction 
with at least 2 additional asthma medications in 6,671 (64.6%) patients, but only 
5,428 (52.6%) received concomitant guideline-recommended treatment with both 
an inhaled corticosteroid and long-acting beta agonist. Asthma-related 
hospitalizations and emergency department (ED) visits were experienced by 6.5% 
(n=673) and 6.9% (n=712) of patients, respectively. The mean (SD) number of 
asthma-related hospitalizations was 1.4 (1.5), with an average stay of 4.6 days; 
the mean (SD) number of asthma-related ED visits was 1.2 (0.5). CONCLUSIONS: 
Despite frequent use of OCS and additional asthma medications, this population 
of patients with asthma experienced high levels of asthma-related 
hospitalizations and ED visits.  
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OBJECTIVES: Chronic obstructive pulmonary disease is a very important problem 
for health systems of different countries trough out the world. For Ukraine as for 
